公开(公告)号：US20170035822A1

公开(公告)日：2017-02-09

申请号：US15304316

申请日：2015-04-17

Applicant: Korea Research Institute of Bioscience and Biotechnology

Inventor： Sei Ryang OH ,  Kyung Seop AHN ,  Seung Hyung KIM ,  In Sik SHIN ,  Hang JIN ,  Jung Hee KIM ,  Hyung Won RYU ,  Wan Yi LI ,  Sang Woo LEE ,  Joong Ku LEE ,  Sang Ho CHOI

IPC: A61K36/22 ,  A61K9/00 ,  A23L33/105 ,  A61K31/12

Abstract: The present invention relates to a composition for suppressing chronic obstructive pulmonary disease (COPD) comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom and, more particularly, to a pharmaceutical composition for preventing or treating COPD comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom; a food composition for preventing or improving COPD, and the compound isolated therefrom. The composition comprising a Pistacia weinmannifolia extract, a fraction thereof, or a compound isolated therefrom, according to the present invention, is not toxic, suppresses the invasion of inflammatory cells into the bronchial tube of a COPD-induced animal model, and effectively suppresses the expression of CXCL-1, TNF-α, or MIP-2. In addition, due to the use of a safety-proven herbal drug as a raw material, the composition of the present invention can resolve various side-effects of existing therapeutic agents for COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, and acute and chronic inflammation, and thus can be effectively used as a composition for preventing, treating and remedying COPD.

Abstract translation: 本发明涉及一种抑制慢性阻塞性肺疾病（COPD）的组合物，其包含维斯特氏菌提取物，其分数或从其分离的化合物，更具体地，涉及用于预防或治疗COPD的药物组合物，所述药物组合物包含猕猴桃提取物（Pistacia weinmannifolia extract） ，其一部分，或从其分离的化合物; 用于预防或改善COPD的食物组合物和从其分离的化合物。 根据本发明的包含猕猴桃提取物，其馏分或从其分离的化合物的组合物是无毒的，抑制炎性细胞侵入COPD诱导的动物模型的支气管中，并有效地抑制 CXCL-1，TNF-α或MIP-2的表达。 此外，由于使用经安全验证的草药作为原料，本发明的组合物可以解决现有的COPD治疗剂，慢性阻塞性支气管炎，慢性细支气管炎，肺气肿，多发性硬化症， 和急性和慢性炎症，因此可以有效地用作预防，治疗和治疗COPD的组合物。

公开(公告)号：US20170266142A1

公开(公告)日：2017-09-21

申请号：US15384302

申请日：2016-12-19

Applicant: YUNGJIN PHARMACEUTICAL CO., LTD ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Yongnam LEE ,  Ji-seok YOO ,  Dae-hee SHIN ,  Byung-hwan RYOO ,  Kyung Seop AHN ,  Sei Ryang OH ,  Hyeong Kyu LEE ,  In Sik SHIN ,  Doo Young KIM ,  Ok-Kyoung KWON ,  Hyuk Hwan SONG ,  Seung Hyung KIM ,  SuUi LEE

IPC: A61K31/192 ,  A61K36/80 ,  A61K31/7048 ,  A23L33/105 ,  A61K31/194

CPC classification number: A61K31/192 ,  A23L33/105 ,  A61K31/194 ,  A61K31/7048 ,  A61K36/80 ,  A61K2236/00

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

公开(公告)号：US20160199339A1

公开(公告)日：2016-07-14

申请号：US14912920

申请日：2014-08-19

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  In Sik SHIN ,  Na-Rae SHIN ,  Tae-Suk LEE ,  JongKoo KANG ,  Young-Sik JUNG ,  Yong-Hae HAN ,  Ki Young SOHN

IPC: A61K31/231

CPC classification number: A61K31/231 ,  A23K20/00 ,  A23L33/40 ,  A23V2002/00 ,  A61K35/32

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Abstract translation: 本发明涉及一种含有单乙酰基二酰基甘油化合物作为预防或治疗哮喘的活性成分的药物组合物，以及用于预防或治疗哮喘的功能保健食品组合物。 本发明的单乙酰基二酰基甘油化合物抑制作为小鼠T细胞淋巴瘤细胞的EL-4细胞中IL-4的表达，降低哮喘诱发的动物模型中气道的超敏反应，并抑制炎症细胞浸润到支气管 管。 此外，本发明的化合物抑制血清和支气管肺泡灌洗液中IgE的产生，具有抑制肺中Th2细胞因子（IL-4，IL-5和IL-13）表达的优异效果 从而克服目前使用的哮喘治疗剂的副作用，没有毒性，表现出优异的治疗效果，因此可用作预防，治疗和缓解哮喘的组合物。

公开(公告)号：US20170217982A1

公开(公告)日：2017-08-03

申请号：US15328056

申请日：2015-07-22

Applicant: YUNGJIN PHARMACEUTICAL CO., LTD ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Yongnam LEE ,  Ji-seok YOO ,  Dae-hee SHIN ,  Byung-hwan RYOO ,  Sei-ryang OH ,  Kyung-seop AHN ,  Hyeongkyu LEE ,  Su Ui LEE ,  Hyuk-hwan SONG ,  In Sik SHIN ,  Hyung Won RYU

IPC: C07D493/08 ,  A61K36/68 ,  A23L2/52 ,  A23L33/155 ,  A23L33/15 ,  A23L33/16 ,  A61K31/357 ,  A23L33/105

CPC classification number: C07D493/08 ,  A23L2/52 ,  A23L33/105 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23V2002/00 ,  A61K31/357 ,  A61K36/68 ,  A61K36/80 ,  C07H17/04

Abstract: A compound (3R,5S,5aS,6R,7S,8R,8aS)-8-chloro-8a-hydroxy-5-(2-hydroxy acetoxy) hexahydro-1H-3,6-methanocyclopenta[e][1,3]dioxepin-7-yl 3,4-dihydroxybenzoate (KS534), the isomer thereof, the pharmaceutically acceptable salt or solvates thereof, a composition comprising the same as an active ingredient for treating allergic disease, inflammatory disease, asthma or chronic obstructive pulmonary disease (COPD)

公开(公告)号：US20170042854A1

公开(公告)日：2017-02-16

申请号：US14912765

申请日：2014-08-19

Applicant: ENZYCHEM LIFESCIENCES CORPORATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Sei-Ryang OH ,  Kyung Seop AHN ,  Su Ui LEE ,  In Sik SHIN ,  Ok-Kyoung KWON ,  Seung Hyung KIM ,  Chan Mi CHUN ,  Tae-Suk LEE ,  Yong-Hae HAN ,  Ki Young SOHN ,  JongKoo KANG ,  Hye Kyung KIM

IPC: A61K31/231

CPC classification number: A61K31/231

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating chronic obstructive pulmonary diseases, and a functional health food composition for treating or preventing chronic obstructive pulmonary diseases. The monoacetyldiacylglycerol compound of the present invention inhibits the IL-4 expression in EL-4 cells and inhibits the infiltration of inflammatory cells into the bronchial tube in an animal model. In addition, the compounds of the present invention have an excellent effect of inhibiting the expression of CXCL-1, TNF-α, or MIP-2, thereby overcoming side effects of the currently used therapeutic agents for chronic obstructive pulmonary diseases, having no toxicity, and exhibiting a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating chronic obstructive pulmonary diseases.

Abstract translation: 本发明涉及含有单乙酰二酰基甘油化合物作为预防或治疗慢性阻塞性肺疾病的活性成分的药物组合物，以及用于治疗或预防慢性阻塞性肺疾病的功能保健食品组合物。 本发明的单乙酰基二酰基甘油化合物抑制EL-4细胞中的IL-4表达，并且在动物模型中抑制炎性细胞浸润到支气管中。 此外，本发明的化合物具有抑制CXCL-1，TNF-α或MIP-2的表达的优异效果，从而克服了目前使用的治疗剂对于无毒性的慢性阻塞性肺疾病的副作用 并且具有优异的治疗效果，因此可用作预防，治疗和缓解慢性阻塞性肺疾病的组合物。

公开(公告)号：US20160051612A1

公开(公告)日：2016-02-25

申请号：US14780503

申请日：2014-04-09

Applicant: YUNGJIN PHARMACEUTICAL CO., LTD. ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Yongnam LEE ,  Ji-seok YOO ,  Dae-hee SHIN ,  Byung-hwan RYOO ,  Kyung Seop AHN ,  Sei Ryang OH ,  Hyeong Kyu LEE ,  In Sik SHIN ,  Doo Young KIM ,  Ok-Kyoung KWON ,  Hyuk Hwan SONG ,  Seung Hyung KIM ,  SuUi LEE

IPC: A61K36/68 ,  A61K31/192 ,  A61K31/7048

CPC classification number: A61K31/192 ,  A23L33/105 ,  A61K31/194 ,  A61K31/7048 ,  A61K36/80 ,  A61K2236/00

Abstract: A composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof. Inventive purified extract and compounds showed potent anti-COPD activity without beta-2-receptor agonistic response through various in vivo tests as well as in vitro test. Therefore, it can be used as the therapeutics or functional health food for treating and preventing chronic obstructive pulmonary disease (COPD).

Abstract translation: 一种组合物，其包含从Pseudolysimachion rotundum var。 含有大量活性成分的亚结构或从其分离的化合物作为治疗慢性阻塞性肺部疾病的活性成分及其用途。 发明纯化的提取物和化合物通过各种体内试验以及体外试验显示出有效的抗COPD活性，而没有β-2-受体激动反应。 因此，它可以用作治疗和预防慢性阻塞性肺疾病（COPD）的治疗剂或功能性保健食品。